Jupiter Topco LLC acquired a new position in Erasca, Inc. (NASDAQ:ERAS – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 76,600 shares of the company’s stock, valued at approximately $1,404,000.
A number of other hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Erasca in the 2nd quarter worth approximately $387,544,000. ARCH Venture Management LLC purchased a new position in shares of Erasca during the 2nd quarter valued at about $129,917,324. Spruce Street Capital LP purchased a new stake in Erasca during the fourth quarter worth $14,469,000. Janus Henderson Group PLC purchased a new stake in Erasca during the first quarter worth $59,988,000. Finally, Commodore Capital LP acquired a new stake in Erasca during the first quarter valued at $51,372,000. 67.78% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
ERAS has been the topic of a number of analyst reports. HSBC set a $20.00 target price on Erasca in a research report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. Mizuho reduced their target price on Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Bank of America lifted their price target on shares of Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Finally, Wolfe Research set a $16.00 price target on shares of Erasca in a report on Thursday, June 4th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Erasca currently has an average rating of “Moderate Buy” and a consensus target price of $22.09.
Erasca Stock Down 0.4%
Shares of NASDAQ ERAS opened at $16.19 on Friday. The firm has a 50-day simple moving average of $18.35 and a 200-day simple moving average of $15.70. The stock has a market capitalization of $5.66 billion, a price-to-earnings ratio of -17.04 and a beta of 0.64. Erasca, Inc. has a 52 week low of $1.47 and a 52 week high of $24.28.
Erasca (NASDAQ:ERAS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). As a group, equities research analysts expect that Erasca, Inc. will post -0.49 EPS for the current year.
About Erasca
Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.
Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.
Read More
- Five stocks we like better than Erasca
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
